Abstract
Acute gastroenteritis is one of the most common infectious diseases of childhood. Its symptoms are vomiting, diarrhea, and dehydration. In the emergency ward, intravenous rather than oral rehydration is usually preferred because of the high likelihood of emesis. Treatments to reduce emesis are of value in improving the rehydration procedure. Our study is a double-blind randomized trial and proposes the use of ondansetron as an antiemetic drug to treat children with acute gas-troenteritis. Seventy-four in-patients, aged 3 months to 15 years, were enrolled and randomly assigned to an ondansetron or placebo group. Inclusion criteria were the diagnosis of acute gastroenteritis and the absence of other diseases or allergies to drugs. A single bolus (0.15 mg/kg) of ondansetron was injected intravenously; normal 0.9% saline solution was used as a placebo. This treatment induced vomiting cessation in the ondansetron group significantly in comparison to the placebo group. The length of the hospital stay and the oral rehydration fluid volume were similar in the two groups and no adverse effects were noticed. Thus, safety, low cost, and overall benefit of ondansetron treatment suggests that this drug can be administered successfully to children with acute gastroenteritis.
Highlights
Intravenous ondansetron administration in a double-blind trial in the emergency department has significantly reduced emesis, diarrhea, and hospital admission rates, confirming the cost-benefit ratio associated with this pharmaceutical approach.[7]
Based on this preliminary evidence, our present study shows the result of a single dose of intravenous ondansetron in the in-patient setting in Thai children
Our study was a prospective, double-blind, randomized comparison between ondansetron and a placebo to reduce emesis in children affected by acute gastroenteritis
Summary
Our study was a prospective, double-blind, randomized comparison between ondansetron and a placebo to reduce emesis in children affected by acute gastroenteritis. Safety, low cost, and overall in the 24 hours prior to admission and had two, and were assigned to the ondansetron benefit of ondansetron treatment suggests acute gastroenteritis symptoms, were eligible group or placebo group. After intravenous that this drug can be administered successful- for the study. Children who met eligible criteria were asked fluid resuscitation, patients received a single to sign a written informed consent form.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.